ImmunoGen, Inc. (IMGN) NASDAQ

31.24

+0.005(+0.02%)

Updated at February 09, 2024 03:58PM

Currency In USD

ImmunoGen, Inc.

Address

830 Winter Street

Waltham, MA 02451-1477

United States of America

Phone

781 895 0600

Sector

Healthcare

Industry

Biotechnology

Employees

277

First IPO Date

November 17, 1989

Key Executives

NameTitlePayYear Born
Mark Joseph EnyedyPresident, Chief Executive Officer & Director1.28M1964
Michael J. VasconcellesChief Medical Officer304,6201963
Lauren A. WhiteSenior Vice President & Chief Financial Officer537,5321979
Theresa G. WingroveSenior Vice President of Regulatory Affairs & Quality548,2051958
Stacy A. CoenSenior Vice President & Chief Business Officer584,0421971
Anabel ChanHead of Investor Relations0N/A
Daniel S. CharSenior Vice President, Chief Legal Officer & Secretary01962
Audrey BerganSenior Vice President & Chief HR Officer0N/A
Courtney O'KonekSenior Director of Corporation Communications & Investor Relations0N/A
Isabel KalofonosSenior Vice President & Chief Commercial Officer0N/A

Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.